var data={"title":"Caspofungin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Caspofungin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5831?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=caspofungin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Caspofungin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=caspofungin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Caspofungin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146788\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cancidas</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146789\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cancidas</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146812\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antifungal Agent, Parenteral;</li>\n      <li>\n        Echinocandin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146793\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Duration of caspofungin treatment should be determined by patient status and clinical response.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Aspergillosis, invasive (salvage therapy):</b> IV: Initial dose: 70 mg on day 1; subsequent dosing: 50 mg once daily. Duration of therapy should be a minimum of 6 to 12 weeks and depends on site of infection, extent of disease, and level/duration of immunosuppression (IDSA [Patterson 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidemia and other </b> <b><i>Candida </i></b> <b>infections: </b>IV: Initial dose: 70 mg on day 1; subsequent dosing: 50 mg once daily; generally continue for at least 14 days after the last positive culture or longer if neutropenia warrants. Higher doses (150 mg once daily infused over ~2 hours) compared to the standard adult dosing regimen (50 mg once daily) have not demonstrated additional benefit or toxicity in patients with invasive candidiasis (Betts 2009). <b>Note:</b> IDSA Candidiasis guidelines recommend transition to fluconazole (usually after 5 to 7 days in non-neutropenic patients) in clinically stable patients with fluconazole-susceptible isolates and negative repeat cultures (IDSA [Pappas 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Candida </i></b>\n      <b> infection, prophylaxis in neutropenic cancer patients at substantial risk (off-label use): </b>IV: 50 mg once daily (Mattiuzzi 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis, chronic disseminated (hepatosplenic) (off-label use):</b> IV: Initial dose: 70 mg on day 1; subsequent dosing: 50 mg daily for several weeks, followed by oral fluconazole therapy (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis, empiric therapy (non-neutropenic ICU patients) (off-label use): </b>IV: Initial dose: 70 mg on day 1; subsequent dosing: 50 mg once daily. Consider discontinuing after 4 to 5 days in patients with no clinical response; continue treatment for 2 weeks in patients who improve on antifungal therapy (IDSA [Pappas 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis, esophageal:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer&rsquo;s labeling: 50 mg once daily; continue for 7 to 14 days after symptom resolution. <b>Note:</b> The majority of patients studied for this indication also had oropharyngeal involvement.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate recommendations: Initial dose: 70 mg on day 1; subsequent dosing: 50 mg daily; may transition to oral fluconazole therapy once oral intake tolerable. In patients with fluconazole-refractory disease, continue caspofungin for 14 to 21 days (Pappas [IDSA 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis, esophageal, in HIV-infected patients (alternative agent) (off-label use):</b> IV: 50 mg once daily; continue for 14 to 21 days. <b>Note:</b> A higher rate of relapse has been reported with echinocandins than with fluconazole (HHS [OI adult 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis, intravascular infections (native or prosthetic valve endocarditis, infection of implantable cardiac devices, suppurative thrombophlebitis) (off-label use):</b> IV: 150 mg daily. For native or prosthetic valve endocarditis, therapy should continue for at least 6 weeks after valve replacement surgery (longer durations in patients with abscesses or other complications); for patients with implantable cardiac devices, therapy should continue for 4 to 6 weeks after surgery (4 weeks for infections limited to generator pockets and at least 6 weeks for infections involving the wires); for suppurative thrombophlebitis, continue for at least 2 weeks after candidemia has cleared. <b>Note:</b> Step-down to fluconazole therapy is recommended in clinically stable patients with fluconazole-susceptible isolates and negative repeat cultures (IDSA [Pappas 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis, osteoarticular infections (osteomyelitis or septic arthritis) (alternative therapy) (off-label use):</b> IV: 50 to 70 mg daily for at least 14 days, followed by fluconazole (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis, prophylaxis against invasive candidiasis (high-risk ICU patients in units with a high rate of invasive candidiasis) (alternative therapy; off-label use):</b> IV: Loading dose: 70 mg on day 1, then 50 mg daily (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis, oropharyngeal (refractory disease) (alternative therapy) (off-label use): </b>IV: Initial dose: 70 mg on day 1; subsequent doses: 50 mg once daily (Pappas [IDSA 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Fungal infections, empiric therapy (neutropenic patients):</b> IV: Initial dose: 70 mg on day 1; subsequent dosing: 50 mg once daily; continue until resolution of neutropenia; if fungal infection confirmed, continue for a minimum of 14 days (continue for at least 7 days after resolution of both neutropenia and clinical symptoms); if clinical response inadequate, may increase up to 70 mg once daily if tolerated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment with concomitant use of an enzyme inducer:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Patients receiving rifampin:</i> 70 mg caspofungin once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Patients receiving carbamazepine, dexamethasone, efavirenz, nevirapine, <b>or</b> phenytoin (and possibly other enzyme inducers):</i> May require an increased dose of caspofungin 70 mg once daily.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146803\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=caspofungin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Caspofungin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Aspergillosis (invasive), candidemia, esophageal candidiasis, and fungal infections (empiric therapy, neutropenic patients):</b> Infants &ge;3 months, Children, and Adolescents &le;17 years: IV: Initial dose: 70 mg/m<sup>2</sup> on day 1, subsequent dosing: 50 mg/m<sup>2</sup> once daily, if clinical response inadequate, may increase to 70 mg/m<sup>2</sup> once daily if tolerated (maximum daily dose, loading or maintenance: 70 mg). Duration of caspofungin treatment should be determined by patient status and clinical response; refer to adult dosing for indication-specific recommended durations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis, esophageal, in HIV-infected patients (alternative agent) (off-label use):</b> Adolescents: IV: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment with concomitant use of an enzyme inducer:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Patients receiving rifampin:</i> 70 mg/m<sup>2</sup> once daily (maximum daily dose: 70 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Patients receiving carbamazepine, dexamethasone, efavirenz, nevirapine, or phenytoin (and possibly other enzyme inducers):</i> Consider 70 mg/m<sup>2</sup> once daily (maximum daily dose: 70 mg/day)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146794\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146795\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">End-stage renal disease (ESRD) requiring dialysis: Poorly dialyzed; no supplemental dose or dosage adjustment necessary in patients on intermittent hemodialysis (IHD). No supplemental dose or dosage adjustment needed in peritoneal dialysis or continuous renal replacement therapy (eg, CVVHD) (Aronoff 2007; Heintz 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146796\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate impairment (Child-Pugh class B): 70 mg on day 1 (where recommended), followed by 35 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children: Mild to severe impairment (Child-Pugh classes A, B, or C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146769\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as acetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg (1 ea); 70 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as acetate [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cancidas: 50 mg (1 ea); 70 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg (1 ea); 70 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146756\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146772\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Infuse slowly, over ~1 hour. Do not administer by IV bolus.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146770\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Aspergillosis, invasive:</b> Treatment of invasive aspergillosis in patients &ge;3 months of age who are refractory to or intolerant of other therapies (eg, amphotericin B, lipid formulations of amphotericin B, itraconazole).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Has not been studied as initial therapy for invasive aspergillosis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidemia and other <i>Candida </i> infections: </b>Treatment of candidemia and the following candida infections in patients &ge;3 months of age: Intra-abdominal abscesses, peritonitis, and pleural space infections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Has not been studied in endocarditis, osteomyelitis, and meningitis due to <i>Candida</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis, esophageal:</b> Treatment of esophageal candidiasis in patients &ge;3 months of age.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Not approved for the treatment of oropharyngeal candidiasis (OPC).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Fungal infections, empiric therapy (neutropenic patients):</b> Empiric therapy for presumed fungal infections in febrile, neutropenic patients &ge;3 months of age.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25725033\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Candida infection, prophylaxis in neutropenic cancer patients at substantial risk; Candidiasis, chronic disseminated (hepatosplenic); Candidiasis, empiric therapy (non-neutropenic ICU patients); Candidiasis, esophageal, in HIV-infected patients (adolescents and adults); Candidiasis, intravascular infections; Candidiasis, oropharyngeal (refractory disease); Candidiasis, osteoarticular infections; Candidiasis, prophylaxis against invasive candidiasis (high-risk ICU patients in units with a high rate of invasive candidiasis)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146762\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (adults: 3% to 20%; infants, children, and adolescents: 9%), peripheral edema (adults: 6% to 11%), tachycardia (7% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Chills (adults: 9% to 23%; infants, children, and adolescents: 13%), headache (9% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (4% to 23%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (adults: 6% to 27%; infants, children, and adolescents: 7%), vomiting (6% to 17%), nausea (adults: 5% to 15%; infants, children, and adolescents: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Decreased hemoglobin (adults: 18% to 21%), decreased hematocrit (adults: 13% to 18%), decreased white blood cell count (adults: 12%), anemia (adults: 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum alkaline phosphatase (adults: 9% to 22%), increased serum ALT (adults: 4% to 18%; infants, children, and adolescents: 5%), increased serum AST (adults: 6% to 16%; infants, children, and adolescents: 2%), increased serum bilirubin (adults: 5% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Localized phlebitis (adults: 18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (adults: 3% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Respiratory failure (adults: 2% to 20%), cough (adults: 6% to 11%), pneumonia (adults: 4% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Infusion related reaction (20% to 35%), fever (6% to 30%), septic shock (adults: 11% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (5% to 9%), atrial fibrillation (&lt;5%), bradycardia (&lt;5%), cardiac arrhythmia (&lt;5%), edema (&lt;5%), flushing (&lt;5%), myocardial infarction (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Anxiety (&lt;5%), confusion (&lt;5%), depression (&lt;5%), dizziness (&lt;5%), drowsiness (&lt;5%), fatigue (&lt;5%), insomnia (&lt;5%), seizure (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Erythema (5% to 9%), pruritus (infants, children, and adolescents: 6%), skin lesion (&lt;5%), urticaria (&lt;5%), decubitus ulcer (adults: 3% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypomagnesemia (adults: 7%), hyperglycemia (adults: 6%), hypokalemia (5% to 6%), hypercalcemia (&lt;5%), hypervolemia (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (4% to 9%), mucosal inflammation (4% to 6%), abdominal distention (&lt;5%), anorexia (&lt;5%), constipation (&lt;5%), decreased appetite (&lt;5%), dyspepsia (&lt;5%), upper abdominal pain (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (&lt;5%), nephrotoxicity (adults: 3%; serum creatinine &ge;2 x baseline value or &ge;1 mg/dL in patients with serum creatinine above ULN range)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Blood coagulation disorder (&lt;5%), febrile neutropenia (&lt;5%), neutropenia (&lt;5%), petechia (&lt;5%), thrombocytopenia (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Decreased serum albumin (adults: 7%), hepatic failure (&lt;5%), hepatomegaly (&lt;5%), hepatotoxicity (&lt;5%), hyperbilirubinemia (&lt;5%), jaundice (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Sepsis (adults: 5% to 7%), bacteremia (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Catheter infection (infants, children, and adolescents: 9%), infusion site reaction (&lt;5%; pain/pruritus/swelling)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (&lt;5%), back pain (&lt;5%), limb pain (&lt;5%), tremor (&lt;5%), weakness (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Hematuria (adults: 10%), increased blood urea nitrogen (adults: 4% to 9%), renal failure (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (adults: 9%), pleural effusion (adults: 9%), respiratory distress (adults: &le;8%), rales (adults: 7%), epistaxis (&lt;5%), hypoxia (&lt;5%), tachypnea (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, erythema multiforme, exfoliation of skin, hepatic necrosis, hepatitis, histamine release (including facial swelling, bronchospasm, sensation of warmth), increased gamma-glutamyl transferase, pancreatitis, renal insufficiency, Stevens-Johnson syndrome, swelling, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146775\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to caspofungin or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for echinocandin antifungals is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146760\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Increased transaminases and rare cases of clinically significant hepatic dysfunction (including failure and hepatitis) have been reported in pediatric and adult patients. Monitor liver function tests during therapy; if tests become abnormal or worsen, consider discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Anaphylaxis, other hypersensitivity reactions, histamine-related reactions (eg, angioedema, facial swelling, bronchospasm, rash, sensation of warmth), and cases of Stevens-Johnson syndrome and toxic epidermal necrolysis (some fatal) have been reported. Discontinue if a hypersensitivity reaction occurs. Administer supportive treatment if needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Dosage reduction required in adults with moderate hepatic impairment (Child-Pugh class B); safety and efficacy have not been established in children with any degree of hepatic impairment and adults with severe hepatic impairment (Child-Pugh class C).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298979\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146764\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9175&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May enhance the adverse/toxic effect of Caspofungin. CycloSPORINE (Systemic) may increase the serum concentration of Caspofungin. Management: Weigh potential benefits of caspofungin against a possible elevated risk of hepatotoxicity.  Monitor liver function and re-evaluate treatment in patients with abnormal values.  Mild transaminase elevations may occur relatively commonly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inducers of Drug Clearance: May decrease the serum concentration of Caspofungin. Management: Consider using an increased caspofungin dose of 70 mg daily in adults (or 70 mg/m<sup>2</sup>, up to a maximum of 70 mg, daily in pediatric patients) when coadministered with known inducers of drug clearance.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Caspofungin. Management: Caspofungin prescribing information recommends using a dose of 70 mg daily in adults (or 70 mg/m<sup>2</sup>, up to a maximum of 70 mg, daily in pediatric patients) who are also receiving rifampin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saccharomyces boulardii: Antifungal Agents (Systemic, Oral) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Caspofungin may decrease the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146766\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146777\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. When treatment of invasive <i>Aspergillus</i> or <i>Candida</i> infections is needed during pregnancy, other agents are preferred (HHS [adult] 2017; IDSA [Pappas 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16431935\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if caspofungin is present in breast milk. The manufacturer recommends that caution be exercised when administering caspofungin to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6273295\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Liver function; anaphylaxis, skin rash, or histamine-related reactions (eg, facial swelling, bronchospasm, sensation of warmth)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146759\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits synthesis of &beta;(1,3)-D-glucan, an essential component of the cell wall of susceptible fungi. Highest activity is in regions of active cell growth. Mammalian cells do not require &beta;(1,3)-D-glucan, limiting potential toxicity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146774\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: CSF concentrations: Nondetectable [&lt;10 ng/mL (n=1)] (S&aacute;ez-Llorens 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~97% to albumin </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Slowly, via hydrolysis and <i>N</i>-acetylation as well as by spontaneous degradation, with subsequent metabolism to component amino acids. Overall metabolism is extensive. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Beta (distribution): 9 to 11 hours (~8 hours in children &lt;12 years); Terminal: 40 to 50 hours; beta phase half-life is 32% to 43% lower in pediatric patients than in adult patients </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (41%; primarily as metabolites, ~1% of total dose as unchanged drug); feces (35%; primarily as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323044\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cancidas Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $405.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">70 mg (1): $421.06</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Caspofungin Acetate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $269.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">70 mg (1): $122.22</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146778\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>BDCASPO (PH);</li>\n      <li>Cancidas (AE, AR, AT, AU, BB, BE, BG, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, IE, IL, IN, IS, IT, JO, JP, KR, KW, LB, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TW, UY, VE, VN);</li>\n      <li>Kansydaz (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 61, 153.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Betts RF, Nucci M, Talwar D, et al, &ldquo;A Multicenter, Double-Blind Trial of a High-Dose Caspofungin Treatment Regimen Versus a Standard Caspofungin Treatment Regimen for Adult Patients With Invasive Candidiasis,&rdquo; <i>Clin Infect Dis</i>, 2009, 48(12):1676-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/19419331/pubmed\" target=\"_blank\" id=\"19419331\">19419331</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cancidas (caspofungin) [prescribing information]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21258094\"></a>Freifeld AG, Bow EJ, Sepkowitz KA, et al; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2011;52(4):e56-e93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/21258094/pubmed\" target=\"_blank\" id=\"21258094\">21258094</a>]</span><span class=\"doi\">10.1093/cid/cir073</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gould FK, Denning DW, Elliott TS, et al, &ldquo;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&rdquo; <i>J Antimicrob Chemother</i>, 2012, 67(2):269-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/22086858/pubmed\" target=\"_blank\" id=\"22086858\">22086858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy</i>. 2009;29(5):562-577.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed August 28, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maertens J, Glasmacher A, Herbrecht R, et al, &ldquo;Multicenter, Noncomparative Study of Caspofungin in Combination With Other Antifungals as Salvage Therapy in Adults With Invasive Aspergillosis,&rdquo; <i>Cancer,</i> 2006, 107(12):2888-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/17103444/pubmed\" target=\"_blank\" id=\"17103444\">17103444</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16377679\"></a>Mattiuzzi GN, Alvarado G, Giles FJ, et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancices. <i>Antimicrob Agents Chemother</i>. 2006;50(1):143-147.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/16377679/pubmed\" target=\"_blank\" id=\"16377679\">16377679</a>]</span><span class=\"doi\">10.1128/AAC.50.1.143-147.2006</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mora-Duarte J, Betts R, Rotstein C, et al, &ldquo;Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis,&rdquo; <i>N Engl J Med</i>, 2002, 347(25):2020-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/12490683/pubmed\" target=\"_blank\" id=\"12490683\">12490683</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;62(4):e1-e50. doi: 10.1093/cid/civ933<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/26679628/pubmed\" target=\"_blank\" id=\"26679628\">26679628</a>]</span><span class=\"doi\">10.1093/cid/civ933</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-e60. doi:10.1093/cid/ciw326. http://cid.oxfordjournals.org/content/early/2016/06/22/cid.ciw326.full.pdf+html. Accessed August 8, 2016.27365388</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    S&aacute;ez-Llorens X, Macias M, Maiya P, et al, &quot;Pharmacokinetics and Safety of Caspofungin in Neonates and Infants Less Than 3 Months of Age,&quot; <i>Antimicrob Agents Chemother</i>, 2009, 53(3):869-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/19075070/pubmed\" target=\"_blank\" id=\"19075070\">19075070</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stone EA, Fung HB, and Kirschenbaum HL, &ldquo;Caspofungin: An Echinocandin Antifungal Agent,&rdquo; <i>Clin Ther</i>, 2002, 24(3):351-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/11952021/pubmed\" target=\"_blank\" id=\"11952021\">11952021</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9175 Version 132.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F146788\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F146789\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F146812\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F146793\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F146803\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F146794\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F146795\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F146796\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F146769\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F146756\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F146772\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F146770\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25725033\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F146762\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F146775\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F146760\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298979\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F146764\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F146766\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F146777\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16431935\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F6273295\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F146759\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F146774\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323044\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F146778\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9175|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=caspofungin-patient-drug-information\" class=\"drug drug_patient\">Caspofungin: Patient drug information</a></li><li><a href=\"topic.htm?path=caspofungin-pediatric-drug-information\" class=\"drug drug_pediatric\">Caspofungin: Pediatric drug information</a></li></ul></div></div>","javascript":null}